A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT04033445)

🧪 Interventions in This Study

• Placebo (DRUG)
• Guselkumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (392 Sites)

Showing the first 25 of 392 sites.

• Om Research LLC — Lancaster, California
• UCLA — Los Angeles, California
• Peak Gastroenterology Associates 1 — Colorado Springs, Colorado
• Florida Research Network, LLC — Gainesville, Florida
• University of Florida Health Jacksonville — Gainesville, Florida
• Harmony Medical Research Institute, Inc. — Hialeah, Florida
• UF Health Jacksonville Gastroenterology Emerson — Jacksonville, Florida
• I.H.S. Health. LLC — Kissimmee, Florida
• Columbus Clinical Services LLC — Miami, Florida
• Vista Health Research, LLC — Miami, Florida
• Orlando Health — Orlando, Florida
• Care Access Research, Orlando — Orlando, Florida
• Synexus Clinical Research US Inc 2 — Pinellas Park, Florida
• Univ. of South Florida Med. Group — Tampa, Florida
• Atlanta Gastroenterology Associates — Atlanta, Georgia
• Morehouse School of Medicine — Atlanta, Georgia
• The Emory Clinic — Atlanta, Georgia
• Atlanta Gastroenterology Associates 1 — Atlanta, Georgia
• Atlanta Center For Gastroenterology — Decatur, Georgia
• Gastroenterolgy Associates of Central GA — Macon, Georgia
• University of Chicago — Chicago, Illinois
• Health Science Research Center — Pratt, Kansas
• Tri-State Gastroenterology Assoc — Crestview Hills, Kentucky
• Baystate Medical Center — Springfield, Massachusetts
• Clinical Research Institute of Michigan, LLC — Clinton Township, Michigan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ulcerative Colitis

• A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
• Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
• A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
• CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
• Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota

Explore by condition: All Ulcerative Colitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.